Skip to main content
. 2020 Nov;152(5):475–481. doi: 10.4103/ijmr.IJMR_930_18

Fig. 2.

Fig. 2

Kaplan-Meier survival analysis for progression-free survival (second-line FOLFOX-4 therapy).